Disease · MONDO_0005157

lymphoid neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lymphoid neoplasm. Diseases, record MONDO_0005157. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005157

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lymphoid neoplasm; Open Targets
Open Targets ID: MONDO_0005157; Open Targets
Other names: hematological neoplasm, lymphocytic and plasma cell neoplasm, lymphocytic and plasma cell tumor, lymphocytic and plasma cell tumour, lymphocytic and plasmacytic neoplasm, lymphocytic neoplasm, lymphocytic tumor, lymphocytic tumour, lymphoid and plasma cell tumor, lymphoid and plasma cell tumour, lymphoid and plasmacytic neoplasm, lymphoid and plasmacytic tumor, lymphoid and plasmacytic tumour, lymphoid tumor, lymphoid tumour; Open Targets
NCI Thesaurus: C7065; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 27 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OMIDUBICEL	CHEMBL4298190	Cell	Approval	FDA	2	1	1	Drugs and targets
DOROCUBICEL	CHEMBL5314825	Cell	Approval	EMA Human Drugs	1	0	0	Drugs and targets
OMIDUBICEL NON-CULTURED FRACTION	CHEMBL6068497	Cell	Approval	FDA	1	0	0	Drugs and targets
VINBLASTINE SULFATE	CHEMBL378544	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DARBEPOETIN ALFA	CHEMBL1201566	Protein	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
IRON SUCROSE	CHEMBL1200823	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TREOSULFAN	CHEMBL455186	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets46

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FGFR1	Fibroblast growth factor receptor	2	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR2	Fibroblast growth factor receptor	2	Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2263	Drugs and targets
FGFR3	Fibroblast growth factor receptor	2	Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2261	Drugs and targets
BCL2	Apoptosis regulator Bcl-2	1	Apoptosis regulator Bcl-2 inhibitor	Phase 1/2	https://conductscience.org/library/genes/596	Drugs and targets
BCL2L1	Bcl-2-like protein 1	1	Apoptosis regulator Bcl-X inhibitor	Phase 1/2	https://conductscience.org/library/genes/598	Drugs and targets
BCL2L2	Bcl-2-like protein 2	1	Apoptosis regulator Bcl-W inhibitor	Phase 1/2	https://conductscience.org/library/genes/599	Drugs and targets
BCL2L2-PABPN1	Bcl-2-like protein 2	1	Apoptosis regulator Bcl-W inhibitor	Phase 1/2	https://conductscience.org/library/genes/100529063	Drugs and targets
CDA	Cytidine deaminase	1	Cytidine deaminase inhibitor	Phase 1	https://conductscience.org/library/genes/978	Drugs and targets
CDK1	Cyclin-dependent kinase 1	1	Cyclin-dependent kinase 1 inhibitor	Phase 1	https://conductscience.org/library/genes/983	Drugs and targets
CDK2	Cyclin-dependent kinase 2	1	Cyclin-dependent kinase 2 inhibitor	Phase 1	https://conductscience.org/library/genes/1017	Drugs and targets

1 to 10 of 46

See all 46 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05005442	A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)	Phase 2	192	2025-12-17	Hematological Malignancies	PEMBROLIZUMAB, VIBOSTOLIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04189445	Futibatinib in Patients With Specific FGFR Aberrations	Phase 2	115	2025-10-08	Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)	FUTIBATINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01349101	A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors	Phase 2	78	2025-12-15	Hematological Malignancies	BUSULFAN, CYCLOPHOSPHAMIDE, FLUDARABINE, MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT03011372	A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)	Phase 2	47	2025-11-18	MPN (Myeloproliferative Neoplasms)	PEMIGATINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04865419	Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies	Phase 1	46	2025-06-15	Haematological Malignancies	VORICONAZOLE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01816230	Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM	Phase 1/2	36	2020-09-21	Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)	OMIDUBICEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00557817	Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)	Phase 2/3	125		Hematological Malignancies	IRON SUCROSE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02223598	A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies	Phase 1	120		Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma	CB-5083	Open Targets' reading of its record	ClinicalTrials.gov
NCT00841724	Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies	Phase 2	82		Hematological Malignancies	BUSULFAN, FLUDARABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00406809	A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies	Phase 1/2	81		Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma	NAVITOCLAX	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Futibatinib (Cohort A) vs Futibatinib (Cohort B): deaths from any cause	54 of 87	24 of 28	115	NCT04189445	Trial comparisons
Futibatinib (Cohort A) vs Futibatinib (Cohort B): serious adverse events	23 of 87	6 of 28	115	NCT04189445	Trial comparisons
Myeloablative HSCT vs Reduced Intensity HSCT: deaths from any cause	3 of 33	8 of 45	78	NCT01349101	Trial comparisons
Myeloablative HSCT vs Reduced Intensity HSCT: serious adverse events	5 of 33	5 of 45	78	NCT01349101	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25283774	RESULT	1	PubMed
41180818	DERIVED	1	PubMed
40856555	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
36343893	DERIVED	1	PubMed
33236943	DERIVED	1	PubMed
30523748	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005157

GET https://conductscience.org/api/diseases/v1/MONDO_0005157/drugs?page=2

API reference For AI assistants